Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Tolerated Dose for Postpartum Depression and Pain (PREPARE1)
NCT05907213Phase 1Completed
- Start
- Sep 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ketamine in postoperative pain and postpartum depression (PPD) (4 arms). Primary endpoint: Maximum Tolerated Dose of Ketamine. Started Sep 2023; status: completed.
02
Drugs
ketamine
03
Conditions
postoperative painpostpartum depression (PPD)
Beyond the preview
Go deeper on NCT05907213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907213.